Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula
Condition(s) studied
Investigational drug(s) / intervention(s)
New infant formula: The new formula will be given to infants during the 4-month study period.
Study summary
This study aims to assess the evolution of functional gastrointestinal disorders (FGIDs) in infants fed with a new infant formula, using the Gastrointestinal (GI) and gastroesophageal reflux (GER) (GIGER) scale through an interventional, open-label, non-comparative multicenter study.
Eligibility
Primary outcome measure(s)
- Change from baseline of the Gastrointestinal and Gastroesophageal Reflux (GIGER) scale score — Day 30
The main outcome will be the evolution of the sum score of the Gastrointestinal and Gastroesophageal Reflux (GIGER) scale (Pados et al., 2021). The GIGER score varies from 0 to 180 being the worst.
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Site 02 | Nice | France | Not Yet Recruiting |
| Site 04 | Paris | France | Not Yet Recruiting |
| Site 03 | Toulon | France | Recruiting |
| Site 01 | Vincennes | France | Recruiting |
More United Pharmaceuticals trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06488274 on ClinicalTrials.gov ↗ ← All trials in France